PhotoSonix Medical, Inc., a Philadelphia, PA-based developer of a a new approach for treating acne at home without antibiotics, received over $1.4M in funding.
The round was led by Princeton BioPharma Capital Partners with participation from healthcare executives and entrepreneurs. In conjunction with the funding, Michael Wells, Managing Director, Princeton BioPharma, will be joining PhotoSonix’ Board of Directors.
The company, which also received funding from Ben Franklin Technology Partners of Southeastern Pennsylvania, intends to use the funds to advance development of the CLENS™ device for treating acne.
Led by Mark Schafer, PhD., President, PhotoSonix develops CLENS™ (Coincident Light Energy and Non-focused ultraSound), which combines low level ultrasound stimulation with blue light energy to achieve an anti-bacterial effect, especially in chronic bacterial infections known as biofilms.
The CLENS™ System, which uses a proprietary combination of light and ultrasound to destroy the bacteria that causes acne, is an investigational device and not available for commercial use in the United States.